DESTINY Break-06 study is another continuous trial for HER2-low metastatic BC designed to evaluate the efficacy and safety of DS-8201 combined chemotherapy in the treatment of HR-positive, HER2-low metastatic BC with failure endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.